What smart money is saying about Medpace
5 funds in our archive have pitched Medpace — most recently Optimist Fund in September 2025.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Fund coverage · 5 theses
- Optimist FundSeptember 2025
Medpace is a leading CRO that achieves consistent growth and exceptional margins by focusing on serving small and mid-sized biotech companies with a disciplined, full-service approach under the leadership of its founder-CEO.
Read the full thesis - Madison Mid Cap FundJune 2025
Medpace Holdings is a rapidly growing contract research organization focused on clinical trial services for small biotech companies, led by a committed founder and with significant growth potential despite current market challenges.
Read the full thesis - Mairs and Power Growth FundJune 2025
Medpace Holdings is a leading contract research organization specializing in clinical trials for small and mid-sized biotech and pharmaceutical companies, positioned well in a growing market with a strong competitive advantage.
Read the full thesis - VulcanMarch 2025
Medpace Holdings is a strong clinical CRO that offers full-service drug development solutions, primarily catering to small and midsized biotech firms, and is expected to return to double-digit growth after a flat year in 2025.
Read the full thesis - Giverny CapitalDecember 2024
Medpace Holdings is a leading clinical trial provider for early-stage biopharma companies
Read the full thesis
Read every full thesis on Medpace
Unlock all 5 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→